Alluvi, known as BI 4744, represents a promising breakthrough in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable effectiveness in https://alluvi600853.blogdemls.com/profile